ArticleDrugs in context2026
Cardiovascular effects of doxazosin in the treatment of prostatic hyperplasia.
Article in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxazosin, a selective α1-receptor antagonist, is widely used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, its cardiovascular effects remain clinically relevant, particularly in older patients. This systematic review and meta-analysis evaluated blood pressure, heart rate, headache and vertigo during doxazosin treatment. PubMed/MEDLINE, the Cochrane Library, CNKI, Wanfang Data, Google Scholar and ScienceDirect were searched using Chinese and English terms related to doxazosin, BPH, prostate and cardiovascular outcomes. Sixteen evidence reports were included: 12 primary studies, 2 pooled analyses and 2 secondary review sources that supplied aggregate trial data. The pooled analyses showed no statistically significant difference in systolic blood pressure (MD 1.44, 95% CI -4.17 to 7.06;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.